Bronski 1995 Salb MDI.
Methods | Study design: Randomized, double blind, cross over Study location: United States Wash‐out: 2‐7 days Exercise challenge: Treadmill for 6 min at 85% of max HR Criteria for EIB diagnosis: FEV1 fall >20% after exercise challenge |
|
Participants | Number of subjects: 46 % of males: 59% Age range: 4‐11 years Ethnicity: 87% Caucasians, 13% Others Withdrawal or drop out: 2 |
|
Interventions | Drug administration: Single dose Time of exercise challenge after drug administration: 15 min. Intervention: Albuterol MDI 180 mcg, Albuterol rotacaps 200 mcg Control: Placebo Other drug arms: None Concomitant inhaled corticosteroid (ICS) treatment: Not allowed |
|
Outcomes | Primary available: max FEV1 % fall, % protection Secondary available: Side effects, Number of patients with a max FEV1 % fall <20% |
|
Notes | Industry funded study | |
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Random sequence generation (selection bias) | Unclear risk | Insufficient information |
Allocation concealment (selection bias) | Unclear risk | Insufficient information |
Blinding of participants and personnel (performance bias) All outcomes | Low risk | Double blind study |
Blinding of outcome assessment (detection bias) All outcomes | Unclear risk | Insufficient information |
Incomplete outcome data (attrition bias) All outcomes | Unclear risk | Insufficient information |
Selective reporting (reporting bias) | Unclear risk | Insufficient information |
Other bias | Unclear risk | Insufficient information |